Company intelligence / Profile preview

ORTHOSON

Oxford, England, United Kingdomorthoson.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ORTHOSON is developing a micro-invasive, bio‑structural gel implant designed to restore the mechanical and biological function of degenerated intervertebral discs. The lead product has received FDA Breakthrough Device Designation for degenerative disc disease. Preclinical data show suppression of key inflammatory drivers of degeneration, with first human trials expected soon[2][5].

Therapeutic areas: Neurology
Modalities: DeviceBiomaterial implantHydrogel-based drug delivery therapy (Bio-Structural Gel)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Bio-Structural Gel

Pre-clinical

Indications: Degenerative disc disease, Lower back pain

Partnerships

University of Oxford Institute of Biomedical Engineering[2]University of Sheffield[2]Sheffield Hallam University[2]

Beyond the preview

Go deeper on ORTHOSON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORTHOSON.

Explore the full profile